Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 13/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 13/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 13/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6558073 | 0.79 | SPHK2 (0.46) | SPHK2SPHK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL357852 | 0.72 | — | — | |
| SCHEMBL31374411 | 0.71 | HSP90AA1 (0.56) | SPHK2SPHK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL11614665 | 0.71 | SPHK2 (0.51) | SPHK2SPHK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL13093801 | 0.69 | SPHK2 (0.58) | SPHK2SPHK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL9195334 | 0.66 | SPHK2 (0.50) | SPHK2SPHK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL6558320 | 0.66 | SPHK2 (0.46) | SPHK2SPHK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL6558546 | 0.66 | SPHK2 (0.46) | SPHK2SPHK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL102331 | 0.63 | PDPK1 (0.59) | HSP90AA1LOXL2RAB9AALDH1A1TSHR | |
| SCHEMBL29654070 | 0.62 | HSP90AA1 (0.50) | SPHK2SPHK1CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157084-B1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA CO (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8106053-B2 | 5-phenyl-3-pyridazinone derivative | KOWA COMPANY, LTD. | 2012-01-31 | — | — | US | disclosed |
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2157084-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | SERPINE1, MMP1, PLAT | SPHK2 1114/4885SPHK1 829/4885CYP1A1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.